Effect of beraprost sodium on response to tests of autonomic control of heart rate in patients with diabetes mellitus

Diabetes Research and Clinical Practice

Volumn 31, Issue 1-3, 1996, Pages 119-124

  Noda, Katsumi ^a   Umeda, Fumio ^b   Nawata, Hajime ^b  

^a HARASANSHIN HOSPITAL   (Japan)

^b KYUSHU UNIVERSITY   (Japan)

Author keywords

Autonomic nerve function; Beraprost sodium; Diabetes mellitus; Factor analysis

Indexed keywords

BERAPROST;

ADULT; ARTICLE; AUTONOMIC NERVOUS SYSTEM; AUTONOMIC NEUROPATHY; CLINICAL ARTICLE; CLINICAL TRIAL; DIABETES MELLITUS; FEMALE; HEART RATE; HUMAN; MALE; ORAL DRUG ADMINISTRATION;

EID: 0029996709     PISSN: 01688227     EISSN: None     Source Type: Journal    
DOI: 10.1016/0168-8227(96)01204-1     Document Type: Article

References (21)

1. The Nervous System and Diabetes
2. 1 analogue (TFC-612) prevents a decrease in motor nerve conduction velocity in streptozocin-diabetic rats
3. 1-controlled multicenter trials in patients with diabetic neuropathy and leg ulcers
4. Arterial walls generate from prostaglandin endoperoxides a substance (prostaglandin X) which relaxes strips of mesenteric and coeliac arteries and inhibits platelet aggregation
5. Human arterial and venous tissues generate prostacyclin (prostaglandin X), a potent inhibitor of platelet aggregation
6. 2) in the circulation of the dog
7. 1α in men
8. Effect of a stable prostacyclin analogue on platelet function and experimentally-induced thrombosis in the microcirculaton
9. Effect of beraprost sodium on peripheral circulation insufficiency in rats and rabbits
10. Recent advances in the non-invasive investigation of diabetic autonomic neuropathy
11. Diabetic neuropathy
12. Does a common mechanism induce the diverse complications of diabetes?
13. Capillary number and percentage closed in human diabetic sural nerve
14. Endoneurial blood flow and oxygen tension in the sciatic nerve of rats with experimental diabetic neuropathy
15. Treatment of severely painful diabetic neuropathy with an aldose reductase inhibitor: relief of pain and improved somatic and autonomic nerve function
16. Tolrestat for mild diabetic neuropathy; a 52-week, randomized, placebo-controlled trial
17. Effects of ponalrestat, an aldose reductase inhibitor, on neutrophil killing of Escherichia Coli and autonomic function in patients with diabetes mellitus
18. Aldose reductase inhibition in diabetic neuropathy: clinical and neurophysiological studies of one year's treatment with sorbinil
19. A 12-month randomized controlled study of the aldose reductase inhibitor ponalrestat in patients with chronic symptomatic diabetic neuropathy
20. Near normoglycaemia improved nerve conduction and vibration sensation in diabetic neuropathy
21. The natural history of somatosensory and autonomic nerve dysfunction in relation to glycaemic control during the first 5 years after diagnosis of Type 1 (insulin-dependent) diabetes mellitus